- Conditions
- Advanced Solid Tumor, Lymphoma
- Interventions
- ALPN-202
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • New Haven, Connecticut • Lafayette, Indiana + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Solid Tumor, Lymphoma
- Interventions
- ALPN-202, pembrolizumab KEYTRUDA®
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Boston, Massachusetts • Grand Rapids, Michigan + 2 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- ALPN-101, Placebo
- Drug
- Lead sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 29
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
- Conditions
- Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Valencia, California + 14 more
- Conditions
- Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
- Interventions
- Povetacicept
- Drug
- Lead sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Cooper City, Florida + 11 more
- Conditions
- Immunoglobulin A Nephropathy
- Interventions
- Povetacicept, Placebo (matched to Povetacicept)
- Drug
- Lead sponsor
- Alpine Immune Sciences Inc, A Subsidiary of Vertex
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Graft Vs Host Disease
- Interventions
- ALPN-101
- Drug
- Lead sponsor
- Alpine Immune Sciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 4
- States / cities
- Miami, Florida • Kansas City, Kansas • Nashville, Tennessee + 1 more